Compound Testing (Scout Program)
The Compound Testing (Scout Program) by the International Rett Syndrome Foundation speeds up preclinical testing of potential Rett syndrome treatments using a specialized mouse model.
Funder: International Rett Syndrome Foundation
Due Dates: Rolling (applications accepted year-round)
Funding Amounts: No fixed award amount; support typically includes access to preclinical compound testing in a Rett syndrome mouse model (in-kind or negotiated case-by-case).
Summary: Accelerates preclinical screening of new or repurposed compounds for Rett syndrome using a dedicated mouse model.
Key Information: Applicants must contact IRSF directly to clarify scope, eligibility, and support details.
Description
The Compound Testing (Scout Program), also known as the IRSF Steven G. Kaminsky Scout Program, is an ongoing initiative by the International Rett Syndrome Foundation (IRSF) to expedite the evaluation of new or repurposed compounds for Rett syndrome. The program leverages a dedicated Rett syndrome mouse model as a drug discovery screening platform, aiming to bridge the gap between preclinical research and clinical trials. It is designed to foster collaborations between basic scientists and biotech industry partners, supporting translational research that could lead to effective treatments or cures for Rett syndrome. The program has already contributed to the advancement of several compounds into clinical trials worldwide.
